Full name

The VIGILANT Study: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as add-on Treatment in COPD Patients With Type 2 Inflammation

NCT Number
NCT07177339
Locations

TBD, multicenter study

Primary Endpoints

Annualized Rate of Moderate/Severe Exacerbations. From Baseline Up to Week 156

Order
3
Disease
COPD
Menu title
VIGILANT: eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Version
AAFP/FMX 2025
Phase
3
Status
Not yet recruiting